Related Experiment Video
Updated: Jun 27, 2026

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Postantibiotic effect of tigecycline against 14 gram-positive organisms
1Department of Pathology, Hershey Medical Center, PA 17033, USA.
Abstract:
The in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of tigecycline were determined for 14 gram-positive and gram-negative organisms. The pneumococcal, staphylococcal, and enterococcal PAEs were 1.9 to 5.1, 2.9 to 5.7, and 3.9 to 6.1 h, respectively, and those for Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii were 1.1 to 5.0, 1.9 to 2.1, 1.7 to 1.8, 1.0 to 1.7, and 0.7 to 3 h, respectively. The PA-SMEs (four times the MIC) ranged from 6.7 to >11 h for gram-positive organisms and from 2.3 to >11.3 h for gram-negative organisms.
Insights
Tigecycline exhibits significant postantibiotic effects (PAEs) and postantibiotic sub-minimum inhibitory concentration effects (PA-SMEs) against various Gram-positive and Gram-negative bacteria, indicating prolonged suppression of bacterial growth after antibiotic exposure.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Tigecycline is a broad-spectrum antibiotic used to treat complex infections.
- Understanding its postantibiotic effects is crucial for optimizing treatment regimens.
Purpose of the Study:
- To determine the in vitro postantibiotic effects (PAEs), postantibiotic sub-MIC effects (PA-SMEs), and sub-MIC effects of tigecycline.
- To evaluate these effects across a panel of 14 Gram-positive and Gram-negative organisms.
Main Methods:
- In vitro susceptibility testing was performed.
- Postantibiotic effects (PAEs) were measured by incubating bacteria with tigecycline and then subculturing.
- Postantibiotic sub-MIC effects (PA-SMEs) were assessed at four times the minimum inhibitory concentration (MIC).
Main Results:
- Tigecycline demonstrated notable PAEs against Gram-positive bacteria (e.g., Enterococcus: 3.9–6.1 h) and Gram-negative bacteria (e.g., Haemophilus influenzae: 1.1–5.0 h).
- PA-SMEs were substantial, ranging from 6.7 to >11 h for Gram-positive and 2.3 to >11.3 h for Gram-negative organisms.
- Variability in effects was observed across different bacterial species.
Conclusions:
- Tigecycline exhibits significant and prolonged postantibiotic effects, suggesting potential for extended dosing intervals or combination therapies.
- The observed PAEs and PA-SMEs highlight tigecycline's sustained activity against a range of pathogens.
- Further clinical studies are warranted to correlate these in vitro findings with clinical outcomes.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness
Inhibitors of Bacterial Protein Synthesis
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Clinical Significance of Antibiotic Resistance
Production of Antibiotics
